Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHILL-1: C+P for Acute Ischemic Stroke
NCT06663631Phase 1Recruiting
- Sponsor
- Capital Medical University
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Aminazin and promethazine in ischemic stroke (5 arms), sponsored by Capital Medical University. Primary endpoint: Incidence and severity of all adverse events (AEs) and severe adverse events (SAEs) at 72 hours. Started Nov 2024; status: recruiting.
02
Drugs
Aminazinpromethazine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06663631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663631.